Sara Ghorashian 医生
概述
莎拉. 格拉珊医生(Dr Sara Ghorashian)毕业于牛津大学，并在英国伦敦Hammersmith和Royal Free医院接受了血液学培训。格拉珊医生在伦敦大学学院(UCL)获得了基因工程T细胞用于癌症免疫疗法的博士学位。近日，她在伦敦大学学院大奥蒙德街儿童健康研究所 (Great Ormond Street Institute of Child Health) 的博士后研究涉及将CD19CAR T细胞转化为治疗儿童急性淋巴细胞白血病 (ALL)的方法。她的主要研究方向为血液恶性肿瘤细胞免疫疗法和T细胞免疫生物学。
她的临床研究兴趣专于儿科恶性血液病，并在所在部门领导细胞疗法和研究。她是两项针对急性淋巴细胞白血病CAR - T细胞研究的联合研究员，并积极参与实施新的研究项目，以改善高危或复发血液恶性肿瘤儿童的预后。
相关资质
新闻和论文发表
Khan AB, Carpenter B, Sousa PSE, Pospori C, Khorshed R, Griffin J, Veliça P, Zech M, Ghorashian S, et. al. Redirection to the bone marrow improves T cell persistence and antitumor functions. J Clin Invest. doi: 10.1172/JCI97454 (epub ahead of print)
Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol.53:164-181.
Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S., et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. DOI: 10.1038/leu.2017.39.
Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S., et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Science and Translational Medicine. 9(374). doi: 10.1126/scitranslmed.aaj2013.
Holler A., Zech M., Ghorashian S., Pike R., et al. Expression of a dominant T cell receptor can reduce toxicity and enhance tumour protection of allogeneic T cell therapy. Haematologica, 101(4):482-90.
Ghorashian, S., Pule, M., Amrolia, P. CD 19 chimeric antigen receptor therapy for haematological malignancies. British Journal of Haematology. 169(4), 463-78
Ghorashian, S., Velica, P., Chua, I., McNicol, A-M., et al. CD8 T cell tolerance to a tumour associated self antigen is reversed by CD4 T cells engineered to express the same T cell receptor. Journal of Immunology 194(3), 1080-9
Buchan, S.L., Manzo, T., Flutter, B., Rogel, A., Edwards, N., Zhang, L., Sivakumaran, S., Ghorashian, S., et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ cells to exit quiescence. Journal of Immunology, 194(1), 125-33
Zimbarra Cabrita, I., Abubaker, M., Layton, M., Ghorashian, S., et al. The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. British Journal of Haematology, 162(3): 400-408.
Xue, S.-A., Gao, L., Ahmadi, M., Ghorashian, S., et al. Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology 2 (1), e22590
Nicholson, E., Ghorashian, S., & Stauss, H. Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Advances in Hematology, 2012, 404081
转诊您的孩子至Sara Ghorashian 医生
如您想转诊您的孩子，请填写下方的转诊申请表。我们的同事会在2个工作日内与您取得联系。
必填项
